Quantcast
Last updated on April 17, 2014 at 11:49 EDT

Latest Convivia Stories

2008-11-11 12:00:06

NOVATO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (BULLETIN BOARD: RPTP) , today announced positive results in its Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia(TM) program. Convivia(TM) is Raptor's proprietary oral formulation of 4-MP designed to reduce systemic acetaldehyde exposure and related symptoms in ALDH2 deficient...